乐观
$100.37
情景价格
$126.160
-1.388 (-1.10%)收盘时
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
Mesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.
Wells Fargo
$94
2026-02-04
Wells Fargo
2026-02-04
目标价
$94
Wells Fargo
$83
2025-12-15
Wells Fargo
2025-12-15
目标价
$83
Jefferies
$115
2025-11-07
Jefferies
2025-11-07
目标价
$115
Wells Fargo
$67
2025-08-07
Wells Fargo
2025-08-07
目标价
$67
Wells Fargo
$100
2025-05-30
Wells Fargo
2025-05-30
目标价
$100
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Mesa Laboratories Reports Q1 2027 Earnings with Mixed Results

Mesa Laboratories to Release Q1 2027 Financial Results on August 10, 2026

Mesa Laboratories Declares Quarterly Dividend of $0.16

Mesa Laboratories Declares Quarterly Dividend

Mesa Laboratories Shares Plunge 19.5% Following Q4 Earnings Report
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).
Mesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.
2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。